介入联合手术治疗门静脉血栓形成7例

目的 评价介入联合手术治疗门静脉血栓形成的疗效。方法 对7例术前确诊为门静脉血栓形成者行开腹经肠系膜上静脉的门静脉内手术取栓、局部溶栓和门静脉狭窄/闭塞段球囊扩张、内支架置入术。2例因小肠坏死、1例因肠腔明显狭窄而同时行部分小肠切除术。结果 7例均治疗成功。术前腹痛、腹胀及消化道症状消失,腹水基本消失。随访3～24个月,平均16个月,均健在,无消化道出血。多普勒超声复查显示门静脉血流通畅。结论 介入联合手术是治疗门静脉血栓形成的安全、有效方法。     

Partial Portal Vein Ligation Plus Thioacetamide: A Method to Obtain a New Model of Cirrhosis and Chronic Portal Hypertension in the Rat

To obtain a new model of chronic portal hypertension in the rat, two classical methods to produce portal hypertension, partial portal vein ligation and the oral administration of thioacetamide (TAA), have been combined. Male Wistar rats were divided into four groups: 1 (control; n?=?10), 2 [triple partial portal vein ligation (TPVL); n?=?9], 3 (TAA; n?=?11), and 4 (TPVL plus TAA; n?=?9). After 3 months, portal pressure, types of portosystemic collateral circulation, laboratory hepatic function tests (aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, and gamma-glutamyl transpeptidase) and liver histology were studied. The animals belonging to group 2 (TPVL) developed extrahepatic portosystemic collateral circulation, associated with mesenteric venous vasculopathy without hepatic destructurization or portal hypertension. Animals from group 3 (TAA) developed cirrhosis and portal hypertension but not extrahepatic portosystemic collateral circulation, or mesenteric venous vasculopathy. Finally, the animals from group 4 (TPVL?+?TAA) developed cirrhosis, portal hypertension, portosystemic collateral circulation, and mesenteric venous vasculopathy. The association of TPVL and TAA can be used to obtain a model of chronic portal hypertension in the rat that includes all the alterations that patients with hepatic cirrhosis usually have. This could, therefore, prove to be a useful tool to study the pathophysiological mechanisms involved in these alterations.     

Intubating conditions after vecuronium and atracurium given in divided doses (the priming technique)

Intubating conditions have been assessed at 60 s following administration of vecuronium 0.1 mg kg-1 or atracurium 0.5 mg kg-1 given either as a single dose after induction of anaesthesia with thiopentone or in divided doses; vecuronium 0.015 mg kg-1 followed 4 or 6 min later by 0.085 mg kg-1, or atracurium 0.075 mg kg-1 followed 4 or 6 min later by 0.425 mg kg-1. In the divided dose groups the smaller initial (priming) dose was given prior to induction of anaesthesia. Onset and duration of clinical relaxation were assessed using a peripheral nerve stimulator. The intubating conditions at 60 s improved significantly, with the use of relaxants in divided doses being acceptable in 80 and 70% of patients, respectively, with vecuronium and atracurium, but the conditions are not as good as those commonly found using suxamethonium. Priming at 6 min has no advantage over priming at 4 min. The onset of complete block was accelerated with priming, but the difference was not significant. The duration of clinical relaxation of vecuronium was significantly prolonged by giving it in divided doses. Unpleasant awareness of muscle weakness was observed in 15 patients, requiring early induction of anaesthesia in five of them.     

V型斜视伴原发性下斜肌功能过强的治疗

目的 探讨Ⅴ型斜视伴原发性下斜肌功能过强的治疗效果。方法根据手术方式将49例Ⅴ型斜视伴下斜肌功能过强惠者分为四组，分别采用水平肌加强减弱术不联合下斜肌切断减弱术（Ⅰ组）、联合单侧下斜肌切断减弱术（Ⅱ组）、联合双侧下斜肌对等切断减弱术（Ⅲ组）及联合双侧下斜肌不对等切断并部分切除减弱术（Ⅳ组）治疗Ⅴ型斜视。结果Ⅴ型斜视伴原发性下斜肌功能过强采用四种方式治疗后，眼位正位，下斜肌功能亢进改善＋～＋＋，双侧下斜肌功能对等，术前术后原在位度数和上下注视25。斜视角之差的差异有非常显著性（P〈0．001）。结论根据单侧或双侧下斜肌功能过强的具体情况来选择不同的手术方式治疗Ⅴ型斜视伴原发性下斜肌功能过强，眼位矫正满意，同时手术方式简单、安全有效。     

经大隐静脉穿刺置管溶栓治疗急性期髂股静脉血栓形成

目的:探讨经大隐静脉入路置管溶栓治疗髂股静脉血栓形成的应用价值。方法:对18例急性期髂股静脉血栓形成的患者在下腔静脉滤器植入术前提下,经大隐静脉入路置管溶栓治疗。结果:18例患者经大隐静脉穿刺成功置管,技术成功率为100%,治疗有效率为100%。置管期间无不良反应及并发症发生;平均住院时间为12.5d。结论:经大隐静脉入路置管溶栓介入治疗急性期髂股静脉血栓操作简便,经济实用,安全有效。     

雷帕霉素靶蛋白反义RNA真核表达载体的构建及其在血管平滑肌细胞中的表达

目的构建雷帕霉素靶蛋白（mTOR）的反义RNA真核表达载体，观察其对血管平滑肌细胞（VSMC）功能的影响。方法提取人VSMC总RNA，逆转录．聚合酶链反应（RT-PCR）扩增mTOR基因cDNA序列，经pGEM-T载体克隆后双酶切，将cDNA序列反向插入绿色荧光蛋白表达载体pEGP-C1，转染VSMC，Westernblot法检测反义表达载体对mTOR蛋白表达的影响，流式细胞仪检测细胞周期的变化。结果经RT-PCR获得664bp产物，T载体克隆后，酶切确定该片段为mTOR基因cDNA，进而构建反义RNA真核表达载体pEGFP-C1-mTOR，测序证明序列正确后转染VSMC，证实其能够显著抑制mTOR蛋白产物表达，转染72h的mTOR蛋白产物表达抑制率达82％，S期细胞由15％降低为7％，凋亡细胞增至9％。VSMC增殖过程在Gx／Go期→S期受阻。结论成功构建mTOR基因的反义RNA真核表达载体。     

Traumatic Injury of the Superior Mesenteric Vein: Ligate,Repair or Shunt?

Abstract We report a case of SMV injury in a critically ill patient. The patient was a 19-year-old woman involved in a motor vehicle collision. Her injuries included grade II splenic and renal lacerations, devascularized and lacerated right and transverse colon, a transected transverse mesocolon, a massive shear injury of her abdominal wall, and two partial SMV transections. At initial damage control laparotomy, the SMV was ligated, the devascularized bowel resected and a temporary abdominal closure applied. At re-operation, a mesocaval shunt using saphenous vein was employed. The shunt failed and the patient required a saphenous vein jump graft. Although visceral vascular injuries are rare, ligation of the SMV in a damage control situation is acceptable. This case study is the first to discuss appropriate treatment when interruption to a patient's collateral visceral venous drainage limits the surgeon’s ability to ligate. In these situations, bypass shunts may be successful.     

髂深血管蒂髂骨-腹内斜肌同蒂双岛状瓣修复下颌复合组织缺损

目的评价以髂深血管为蒂的髂骨—腹内斜肌双岛状瓣（简称同蒂双岛状瓣）修复下颌复合组织缺损的临床应用价值。方法2005年1月至2006年10月,应用同蒂双岛状瓣修复10例下颌骨复合组织缺损（包括下颌骨体部、下颌角和下颌骨升支及其周围软组织,其中有7例还包含髁突的缺损）。结果10例同蒂双岛状瓣移植均获成功,仅1例出现局部轻度感染,换药后二期愈合。术后随访3～24个月,均无肿瘤复发,颌面外形两侧基本对称,咬合关系恢复正常,且供区未见明显的并发症。结论同蒂双岛状瓣具有切口隐蔽、单一,对供区功能影响小,软硬组织复合缺损同期修复效果好等特点,是半侧下颌骨复合周围软组织大型缺损功能重建的较好方案。     

腔内激光治疗大隐静脉曲张192例报告

目的 探讨腔内激光治疗大隐静脉曲张的疗效。方法 2004年7月～2006年3月我院对192例238条肢体大隐静脉曲张行高位结扎、激光烧灼静脉主干和小腿曲张静脉。小腿局部严重曲张的静脉团,另做切口做局部切除或点状抽拨。结果 本组一次治愈率96.2%（229/238）。9例9条肢体术后因仍有少量曲张静脉存在,局麻下行切除或再次激光治愈。114例大隐静脉主干及小腿局部条索状硬结、疼痛;9例皮肤灼伤。术后住院时间4～8 d,平均5.6 d。158例随访1～18个月,平均11.6月,未见复发。结论 腔内激光治疗大隐静脉曲张效果确切,创伤小。